A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina

Plain-language summary

This study examined the safety of the drug Atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer in Argentina. It enrolled patients with this diagnosis who had received at least one dose of Atezolizumab. The trial was a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Hoffmann-La Roche

Start date

12/27/2017

Estimated completion

3/2/2019

Countries

Argentina

Related genes

Locations

• Buenos Aires, Argentina

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Signed an informed consent form submitted to the Administración Nacional de Medicamentos Alimentos y Tecnología Médica (ANMAT)
* Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) non-small cell lung cancer (NSCLC)
* Have received at least one dose of atezolizumab as per local label and clinical practice

Exclusion Criteria:

* Contraindicated atezolizumab therapy